Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sanofi is currently conducting a clinical study titled ‘Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO).’ The study aims to assess the efficacy and safety of dupilumab in treating adults with chronic pruritus of unknown origin, a condition characterized by severe itching without a known cause.
The study involves testing the drug Dupilumab, administered subcutaneously, alongside a non-sedative antihistamine and moisturizer. The purpose is to determine if Dupilumab can effectively reduce the severity of pruritus compared to a placebo.
This Phase 3 study is designed as a randomized, double-blind, placebo-controlled trial with a parallel intervention model. Participants, care providers, investigators, and outcomes assessors are all blinded to the treatment allocations. The primary goal is treatment-focused.
The study began on February 15, 2022, with an estimated completion date in 2025. The last update was submitted on June 25, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might influence market dynamics.
The outcome of this study could significantly impact Sanofi’s stock performance, as positive results may boost investor confidence and market positioning, especially in the dermatological treatment sector. Competitors in the field may also be affected as new treatment options emerge.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.